July 30, 2014
July 29, 2014
July 28, 2014
Office of the Inspector General "OIG" Publishes New Physician Compliance Guidance
The Office of the Inspector General for the U.S. Department of Health and Human Services has published a new guidance document for physicians on compliance with healthcare fraud and abuse laws. The document, A Roadmap for Physicians: Avoiding Medicare Fraud and Abuse, summarizes the five main federal fraud and abuse laws: the False Claims Act; the Anti-Kickback statute; the Physician Self-Referral Law (“Stark”), the Medicare exclusion statute; and the Civil Monetary Penalties (“CMP”) law. These materials then offer guidance on how physicians can comply with these laws in their relations with vendors, payers, and other providers. Examples include practical advice on such issues as coding, documentation, investments in health care business ventures, physician recruitment, and medical director arrangements. These materials may be found on the OIG website by following this link.
Daniel Levinson, HHS Inspector General, and Lew Morris, Chief Counsel to the Inspector General, both alluded to these new resources during testimony on March 2 before the U.S. Senate Committee on Finance, where they spoke on OIG’s collaboration with members of the private sector in their efforts to combat fraud. Messrs. Levinson and Morris also described two other ongoing initiatives aimed at strengthening the integrity of the Medicare and Medicaid programs, involving the targeting of “hot spots” with Medicare Fraud Strike Teams and increased utilization of exclusion and other tools when dealing with “untrustworthy” providers. This testimony is also accessible on the OIG website.
<span class="advertise"> Advertisement </span>
- New Medicare Tax Makes FICA Errors Harder to Correct
- Big Increase in 2014 Service Contract Act Health & Welfare Rate Announced
- Office for Civil Rights (OCR) to Begin Phase 2 of HIPAA Audit Program
- FDA Finalizes Guidance on the Evaluation of 510(k) Substantial Equivalence
- FDA Denies Citizen Petition’s Request to Ban Marketing of Non-Absorbable Surgical Mesh Products for Transvaginal Repair of Pelvic Organ Prolapse
- The FDA’s Informed Consent Draft Guidance: Insights and Challenges for IRBs, Clinical Investigators and Sponsors